Virtual Library

Start Your Search

Meifeng Ye



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-131 - Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer (ID 11784)

      16:45 - 18:00  |  Author(s): Meifeng Ye

      • Abstract
      • Slides

      Background

      Methylsulfonic apatinib showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) as one of the TKIs which specifically inhibits VEGFR-2. We aimed to assess the efficacy of apatinib in each lines of treatment to patients with advanced/metastatic NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively analyzed variables and outcomes of patients with advanced NSCLC, who had received apatinib between January 1, 2016 and April 30, 2018, including: 5 patients of first line treatment, 16 second line treatment, 20 third line treatment and 6 fourth and fifth line treatment.

      4c3880bb027f159e801041b1021e88e8 Result

      The most frequent treatment-related adverse events were hypertension, proteinuria, hand-foot skin reaction and hemoptysis. Among the 47 cases included in the final analysis, the median progression-free survival among patients was 5.66 months specialized in: 0-24.0 months in first line treatment, 0-10.0 in second line treatment, 2.0-10.0 in third line treatment and 0.6-5.4 months in fourth and fifth line treatment. The median overall survival time for apatinib were 25.97 months, 21.4-28.5 months in third line treatment and 0-64.9 months in fourth and fifth line treatment. No significance was found in either PFS and OS among lines of treatment, histology and EGFR mutation status.阿帕替尼 摘要.png

      Figure 1 PFS and OS of apatinib in different lines of treatment

      8eea62084ca7e541d918e823422bd82e Conclusion

      The results indicate the administration of apatinib could be used as an alternative for advanced/metastatic NSCLC patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.